SCHEMBL26083706

SCHEMBL26083706

CO[C@H]1[C@@H](O)[C@@H]([C@@H](O)CCCN)O[C@H]1n1ccc(N)nc1=O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NT5E P21589 1/20 0.53
LMNA P02545 2/20 0.47
THRB P10828 1/20 0.47
MTOR P42345 1/20 0.47
MDM2 Q00987 1/20 0.47
NCOA1 Q15788 1/20 0.47
NCOA3 Q9Y6Q9 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.41
TSHR P16473 1/20 0.39
GLA P06280 1/20 0.39
PDE3A Q14432 2/20 0.38
PDE4D Q08499 1/20 0.38
SLC29A1 Q99808 1/20 0.38
ST6GAL1 P15907 3/20 0.38
P2RY2 P41231 1/20 0.37
CACNA1F O60840 1/20 0.36
ALB P02768 1/20 0.36
MAPT P10636 1/20 0.36
CACNA1D Q01668 1/20 0.36
CACNA1S Q13698 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26692863 1.00 NT5E (0.53) NT5ELMNATHRBMTORMDM2
SCHEMBL26692867 1.00 NT5E (0.53) NT5ELMNATHRBMTORMDM2
SCHEMBL26083563 1.00 NT5E (0.53) NT5ELMNATHRBMTORMDM2
SCHEMBL30256877 0.84 NT5E (0.52) NT5ELMNATHRBMTORMDM2
SCHEMBL30256934 0.84 NT5E (0.52) NT5ELMNATHRBMTORMDM2
SCHEMBL26083705 0.81 SLC28A1 (0.44) SLC29A1P2RY2
SCHEMBL26692833 0.81 SLC28A1 (0.44) SLC29A1P2RY2
SCHEMBL26083562 0.81 SLC28A1 (0.44) SLC29A1P2RY2
SCHEMBL22763978 0.81 SLC28A1 (0.44) SLC29A1P2RY2
SCHEMBL26083551 0.81 SLC28A1 (0.44) SLC29A1P2RY2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11780874-B2 Nucleoside derivative and use thereof YAMASA CORPORATION (JP) 2023-10-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11780874-B2 Nucleoside derivative and use thereof NSUN2, NSUN3, ADAR NT5E 268/4885LMNA 2306/4885THRB 2151/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.